Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2017.1263614
Abstract: ABSTRACT Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by focal pathologic bone resorption due to excessive activity of osteoclasts (OC). Receptor activator of nuclear factor kappa B ligand (RANKL) is essential for… read more here.
Keywords: dmab; denosumab targeting; targeting rankl; rheumatoid arthritis ... See more keywords